Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Bonne J. Adams"'
Autor:
Manmeet S. Ahluwalia, Lisa R. Rogers, Rekha Chaudhary, Herbert Newton, Ahmad Ozair, Atulya A. Khosla, Andrew B. Nixon, Bonne J. Adams, Ben K. Seon, David M. Peereboom, Charles P. Theuer
Publikováno v:
Communications Medicine, Vol 3, Iss 1, Pp 1-7 (2023)
Abstract Background Glioblastoma (GBM), the most lethal primary brain tumor, has limited treatment options upon recurrence after chemoradiation and bevacizumab. TRC105 (carotuximab), a chimeric anti-endoglin (CD105) antibody, inhibits angiogenesis an
Externí odkaz:
https://doaj.org/article/489e8a21a0c84f6195ce4cbc9fe62530
Autor:
Neeraj Agarwal, Judit Kocsis, Charles P. Theuer, Mohamed Darif, Jing Lyu, Sumanta K. Pal, Bonne J. Adams, Mollie deShazo, Kouros Owzar, Thai H. Ho, Toni K. Choueiri, Liz Robertson, Yousef Zakharia, Andrew B. Nixon, Meghara K. Walsh, Russell K. Pachynski, Lajos Géczi, Yingmiao Liu, Alexandr Poprach, Primo N. Lara, Mark D. Starr
Publikováno v:
The oncologist, vol 26, iss 7
Oncologist
Oncologist
Lessons Learned Background Endoglin is an angiogenic receptor expressed on proliferating tumor vessels and renal cell carcinoma (RCC) stem cells that is implicated as a mechanism of resistance to vascular endothelial growth factor receptor (VEGFR) in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4cb3cefb1fe953ed4cc21558dbfb65ff
https://escholarship.org/uc/item/6xc9d29b
https://escholarship.org/uc/item/6xc9d29b
Autor:
Bonne J. Adams, David F. McDermott, Charles P. Theuer, Zhenhua Yuan, Manoj A. Jivani, Guru Sonpavde, Ben K. Seon, Yingmiao Liu, Edwin M. Posadas, M. Dror Michaelson, Andrew B. Nixon, Toni K. Choueiri, Meghara K. Walsh
Publikováno v:
The Oncologist. 24:202-210
Background TRC105 is an IgG1 endoglin monoclonal antibody that potentiates VEGF inhibitors in preclinical models. We assessed safety, pharmacokinetics, and antitumor activity of TRC105 in combination with axitinib in patients with metastatic renal ce
Autor:
Charles P. Theuer, Sandra P. D'Angelo, Steven I. Robinson, Bonne J. Adams, Robert G. Maki, James L. Freddo, Joelle Lam
Publikováno v:
Cancer Research. 81:CT239-CT239
Background: Metastatic undifferentiated pleomorphic sarcoma (UPS) and the genetically related myxofibrosarcoma (MFS) are soft tissue sarcoma (STS) subtypes with poor prognoses. While responses to front line chemotherapy can approach 20%, in the 2nd l
Autor:
Francisco Robert, Charles P. Theuer, Huaqiong Joan Shen, Yonggang Zhao, Yan Xing, Bonne J. Adams, Michael S. Gordon, Linda Lee, Elizabeth Mills, James L. Freddo, Ecaterina Elena Dumbrava, Claire Xu, Jerry Wang, James Lawrence, Alicia A Trigeiro, Yuan Meng
Publikováno v:
Journal of Clinical Oncology. 39:2511-2511
2511 Background: CD73 is implicated in tumor resistance to checkpoint immunotherapy (CPI) and plays a critical role in adenosine-mediated immune suppression. Uliledlimab, a differentiated CD73 antibody, inhibits the adenosine pathway in a non-competi
Autor:
Joelle Lam, Sandra P. D'Angelo, Steven I. Robinson, Bonne J. Adams, James L. Freddo, Charles P. Theuer, Robert G. Maki
Publikováno v:
Journal of Clinical Oncology. 39:TPS11581-TPS11581
TPS11581 Background: Metastatic undifferentiated Pleomorphic Sarcoma (UPS) and the genetically related myxofibrosarcoma (MFS) are soft tissue sarcoma (STS) subtypes with poor prognoses. While responses to front line chemotherapy can approach 20%, eff
Autor:
Sumanta K. Pal, Yousef Zakharia, Christopher W. Ryan, Judit Kocsis, Bruce G. Redman, Thomas Olencki, L. Robertson, Bonne J. Adams, Primo N. Lara, B.E. Simpson, Lajos Géczi, Alexandr Poprach, Neeraj Agarwal, Charles P. Theuer, M. Darif, Mollie deShazo, Toni K. Choueiri, Thai H. Ho, Russell K. Pachynski, László Mangel
Publikováno v:
Annals of Oncology. 30:v362-v363
Background Endoglin is an essential angiogenic receptor expressed on proliferating tumor vessels and RCC stem cells that is implicated as a mechanism of VEGF resistance. TRC105 is an endoglin monoclonal antibody that potentiates the anti-tumor activi
Autor:
Bonne J. Adams, Herbert Hurwitz, Yingmiao Liu, Christel Rushing, Delia Alvarez, Mark D. Starr, Charles P. Theuer, Herbert Pang, John C. Brady, Andrew B. Nixon
Publikováno v:
Molecular cancer therapeutics. 17(10)
TRC105 is an anti-endoglin antibody currently being tested in combination with VEGF inhibitors. In the phase Ib trial, 38 patients were treated with both TRC105 and bevacizumab (BEV), and improved clinical outcomes were observed, despite the fact tha
Autor:
Charles P. Theuer, Bonne J. Adams, Nam Y. Lee, Herbert Hurwitz, Andrew Dellinger, Andrew B. Nixon, Yingmiao Liu, John C. Brady, Mark D. Starr, Herbert Pang
Publikováno v:
Cancer Medicine
TRC105 is an endoglin-targeting drug that possesses anti-angiogenic and antitumor potential. Analysis of the initial phase I trial of TRC105 demonstrated good tolerability and efficacy in cancer patients. In this report, we analyzed multiple circulat
Autor:
Jonathan H. Goldman, Michael S. Gordon, Shawn D. Spencer, Bryan R. Leigh, William D. Figg, Herbert Hurwitz, Ben K. Seon, Charles P. Theuer, David S. Mendelson, Bonne J. Adams, Lee S. Rosen, Michael K. Wong, Delia Alvarez
Publikováno v:
Clinical Cancer Research. 18:4820-4829
Purpose: TRC105 is a chimeric IgG1 monoclonal antibody that binds CD105 (endoglin). This first-in-human, phase I, open-label study assessed safety, pharmacokinetics, and antitumor activity of TRC105 in patients with advanced refractory solid tumors.